Study protocol for a randomized single-center cross-over study: Dapagliflozin treatment in recurring kidney stone patients.

PLoS One · 2025 · PMC12021238 · PMID 40273182

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Within an interim analysis, the phase III study was recommended to be stopped after a median follow-up of 2.4 years because of highly significant positive effects.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.